VIATRIS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 9.21K shares, a 145.23% increase year-over-year.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 11.31K shares, a 32.44% increase year-over-year.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 2.41K shares, a 62.78% decline year-over-year.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 3.84K shares, a 69.82% increase year-over-year.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 18.54K shares, a 68.01% decline from fiscal 2024.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 57.95K shares, a 119.04% increase from fiscal 2023.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 26.46K shares.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 27.61K shares, a 95.25% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 9.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 26.76K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 11.31K shares 10-Q · filed 2026-05-07 | 21.31K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 2.41K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 18.54K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 3.84K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 22.60K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 3.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 21.02K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 8.54K shares 10-Q · filed 2025-05-08 | 48.48K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 6.47K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 57.95K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 2.26K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 61.23K shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | 31.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 66.55K shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | 18.01K shares 10-Q · filed 2024-05-09 | 39.24K shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | 9.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 26.46K shares 10-K · filed 2025-02-27 |
| 2023-09-30 | 7.58K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | |
| 2023-06-30 | 3.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | |
| 2023-03-31 | 5.22K shares 10-Q · filed 2023-05-08 | |
| 2020-12-31 | 27.61K shares 10-K · filed 2023-02-27 | |
| 2019-12-31 | 580.95K shares 10-K · filed 2022-02-28 | |
| 2018-12-31 | 820.60K shares 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |